INCY — INCYTE CORP

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 879169 ·
Last close
$124.82
Market Cap
$25.30B
52W High
$132.60
52W Low
$82.52
ADV30
1,417,176
Next earnings
2026-10-27

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 1,272,676,000 1,168,176,000 324,173,000 303,330,000 7,339,113,000 3,461,114,000 1,716,266,000
Dec 2025 1,506,835,000 1,385,735,000 383,963,000 299,279,000 6,957,973,000 3,097,817,000 1,790,495,000
Sep 2025 1,365,980,000 1,266,980,000 431,296,000 424,169,000 6,330,356,000 2,455,006,000 1,679,162,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,979,703,000
Investing CF
$-224,831,000
Financing CF
$275,239,000
CapEx
$-89,237,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$7.85
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$1,102,704,000
Inventory
$112,542,000
Receivables
$1,125,203,000
ST Investments
$553,365,000
EBIT TTM
$1,969,688,000
Pretax Income TTM
$1,967,363,000
Interest Exp TTM
$2,325,000
Analysts
23

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,819,530,240
EBITDA
$1,942,312,960
Free Cash Flow
$1,180,664,576
Enterprise Value
$20,124,221,440
Total Cash
$4,535,739,904
Total Debt
$38,267,000
Shares Out
202,697,746
Trailing EPS
$7.85
Book Value
$31.57
ROE
30.7%
ROA
16.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 5,141,242,000 1,342,790,000 1,286,650,000 6,957,973,000 1,790,495,000 5,167,478,000 1,413,498,000
Dec 2024 4,241,217,000 101,294,000 32,615,000 5,444,322,000 1,996,694,000 3,447,628,000 335,337,000
Dec 2023 3,695,649,000 655,358,000 597,599,000 6,782,107,000 1,592,270,000 5,189,837,000 496,487,000
Dec 2022 3,394,635,000 591,626,000 340,660,000 5,840,984,000 1,470,865,000 4,370,119,000 969,941,000

TTM Snapshot

Revenues TTM
$3,933,097,000
NetIncome TTM
$548,703,000
OpCashFlow TTM
$0
Assets (Latest)
$6,957,973,000
Forward EPS
$8.89

Max Pain — expiry 2026-12-18

max pain strike: $110.00 · spot: $124.82 · call oi: 2,315 · put oi: 10,840
Expected Move to 2026-12-18: ±$20.55 (16.46%) — implied range $104.27 – $145.37 · ATM straddle on $125.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MEDP Medpace Holdings, Inc. $17.19B $615.94 —
IDXX IDEXX LABORATORIES INC /DE $41.68B $529.06 —
IQV IQVIA HOLDINGS INC. $44.60B $270.97 —
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $14.19B $294.59 —
ICLR ICON PLC $13.55B $175.57 —

News headlines (Yahoo Finance, 1h cache)

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
2026-09-28 12:38 · Yahoo
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
2026-09-25 18:43 · Yahoo
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data
2026-09-24 01:15 · Yahoo
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
2026-09-23 04:53 · Yahoo
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says
2026-09-22 15:45 · Yahoo
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
2026-09-21 11:06 · Yahoo
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
2026-09-20 20:00 · Yahoo
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target
2026-09-20 02:02 · Yahoo
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?
2026-09-17 22:44 · Yahoo
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
2026-09-25 23:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.